The FDA rejected two new products from AbbVie and Grace Therapeutics, citing manufacturing-related concerns. More: FDA snubs AbbVie's prospective Botox heir amid series of manufacturing-related CRLs Source: fierce
read moreAfter a series of setbacks for Sanofi’s tolebrutinib, the French company has scored a victory for the multiple sclerosis candidate. More: Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval Source: fierce
read moreAn established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its new indication and power the franchise to peak sales of $3.1 billion, Guggenheim Securities analysts predicted in a note to investors.
read moreDaiichi Sankyo has postponed its annual report by two weeks, citing additional time needed to review “the supply plans for its oncology products portfolio and development pipeline.” More: Daiichi pushes back annual report, citing reviews amid ‘rapidly changing business conditions’
read moreRoche’s Genentech unit is launching a new multimedia campaign aimed at sharing the stories of people living with diabetes and the impact the disease can have on their vision. More: Genentech wants ‘All Eyes on DME’ as it taps Damon
read more© 1994 - 2026 B.M. Pharmaceuticals